NATCO Pharma gets USFDA tentative approval for its generic Erdafitinib, a treatment for advanced urothelial carcinoma, offering a more affordable option for cancer patients.
Indoco Remedies has received USFDA approval for its ANDA for Lacosamide Oral Solution, a generic version of Vimpat. The approval strengthens the company’s growing footprint in the U.S. generics market.
Union Budget 2026 boosts India’s biopharma and healthcare sectors with Rs 10,000 crore for Biopharma SHAKTI, creating new opportunities for innovation, manufacturing, and patient care.
Pharma stocks are soaring after the Budget 2026 announcement of a Rs 10,000 crore biopharma push. This move under the Biopharma Shakti initiative is set to strengthen India's role in global healthcare, driving investment and innovation.
Wockhardt’s Foviscu (WCK 4282) hits its Phase 3 endpoint, showing clinical cure rates comparable to meropenem for complicated UTIs, including ESBL infections, offering a vital alternative for antibiotic-resistant cases.
Naprod Life Sciences has secured an ANVISA GMP renewal for its Tarapur manufacturing facility, reinforcing its compliance with Brazil’s regulatory standards and supporting continued exports of oncology and specialty pharmaceutical products.
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of Nivolumab in India. This launch provides cancer patients with an affordable, reliable alternative to expensive treatments, ensuring improved access to life-saving therapies.
Novavax has entered a high-value licensing deal with Pfizer, granting access to its Matrix-M adjuvant for future vaccines. The agreement brings upfront cash, milestones, and long-term royalty potential.
Granules India is actively exploring acquisitions in the injectables segment, with deal sizes capped at $50 million, as it targets quality-led growth amid global shortages and rising demand for complex formulations.
Novo Nordisk’s Wegovy pill is seeing encouraging early demand in the U.S., giving the drugmaker a head start in the fast-growing weight-loss market as it competes with Eli Lilly’s upcoming oral treatment.
.jpg)
, CDSCO.jpg)